ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating ...

Q2 2025 Earnings Call Transcript May 12, 2025 Arrowhead Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $2 ...

Learn more about whether Arrowhead Pharmaceuticals, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

ARROWHEAD PHARMACEUTICALS ($ARWR) posted quarterly earnings results on Monday, May 12th. The company reported earnings of $2.75 per share, beating estimates of -$0.20 ...

The Pasadena, Calif., biotechnology company, which uses RNA interference to develop treatments, said Monday it recorded a profit of $370.4 million, or $2.75 a share, during the fiscal second quarter, ...

Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31 ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery ...

--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call ...

Q2 2025 Earnings Conference Call May 12, 2025 4:30 PM ET. Company Participants. Vincent Anzalone - Vice President of Investor Relatio ...